Xilio Therapeutics, Inc. (XLO): Price and Financial Metrics


Xilio Therapeutics, Inc. (XLO): $3.65

-0.32 (-8.06%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add XLO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

XLO Stock Price Chart Interactive Chart >

Price chart for XLO

XLO Price/Volume Stats

Current price $3.65 52-week high $14.86
Prev. close $3.97 52-week low $1.95
Day low $3.50 Volume 144,667
Day high $4.07 Avg. volume 97,423
50-day MA $2.67 Dividend yield N/A
200-day MA $2.81 Market Cap 100.27M

Xilio Therapeutics, Inc. (XLO) Company Bio


Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune system for cancer patients. Its checkpoint inhibitor programs include XTX101, is a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1 clinical trials in patients with solid tumors; and cytokine programs comprise XTX202, XTX301, and XTX401, which are modified form of IL-2 that is masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.


XLO Latest News Stream


Event/Time News Detail
Loading, please wait...

XLO Latest Social Stream


Loading social stream, please wait...

View Full XLO Social Stream

Latest XLO News From Around the Web

Below are the latest news stories about XILIO THERAPEUTICS INC that investors may wish to consider to help them evaluate XLO as an investment opportunity.

Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12

WALTHAM, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that the company will host a live virtual program on Thursday, December 1, 2022, at 12:30 p.m. ET spotlighting Xilio’s clinical-stage molecule XTX301, a tumor-activated, engineered IL-12. The event will feature Diwakar Davar, MBBS, M.Sc., a key opinion leader and assistant professor of

Yahoo | November 23, 2022

Xilio Therapeutics (XLO) Investor Presentation - Slideshow (NASDAQ:XLO)

The following slide deck was published by Xilio Therapeutics, Inc.

Seeking Alpha | November 12, 2022

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results

XTX202, a tumor-activated IL‑2, successfully reached target dose range of 1 mg/kg in ongoing Phase 1 clinical trial; preliminary evidence of increased CD8+ effector T cells and NK cells observed with no signs of vascular leak syndrome

GlobeNewswire | November 9, 2022

Xilio Therapeutics to Present at Cowen 6th Annual ‘IO Next’ Summit

WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that the company will participate in a virtual fireside chat at the Cowen 6th Annual IO Next Summit on Friday, November 11, 2022, at 1:40 p.m. ET. A live webcast of the presentation can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutic

Yahoo | November 4, 2022

Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference

WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that the company will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Thursday, September 29, 2022, at 10:15 a.m. ET.

GlobeNewswire | September 22, 2022

Read More 'XLO' Stories Here

XLO Price Returns

1-mo 35.69%
3-mo 59.39%
6-mo 21.26%
1-year -73.18%
3-year N/A
5-year N/A
YTD 35.69%
2022 -83.19%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6494 seconds.